Clinical trials: Blood Plasma Therapy
Multiple Myeloma
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple…
- Trial name
- NCT02278315
- Testing
- I-131-CLR1404, dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Cellectar Biosciences, Inc.
Polycystic Ovarian Syndrome
Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome
Objective: 1. To investigate the changes in the levels of interleukin-6 and interleukin-8 after 3 months treatment with metformin alone and combination of metformin and pioglitazone in patients with polycystic ovarian syndrome…
- Trial name
- NCT03117517
- Testing
- Metformin, Metformin, Pioglitazone
- Where
- Pakistan
- Volunteers
- 106 people
- Sponsor
- Khyber Medical University Peshawar
Multiple Myeloma
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)
This study is a Phase Ib open label, single arm, adaptive multicentre trial. Patients with newly diagnosed Multiple Myeloma (MM) will be treated with Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) in combination with…
- Trial name
- CyBorD-Dara (NCT02955810)
- Testing
- Daratumumab, Cyclophosphamide, Bortezomib
- Where
- Ireland
- Volunteers
- 18 people
- Sponsor
- National University of Ireland, Galway, Ireland
Rosacea, Papulopustular
Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device
10-13 patients will be enrolled to receive split face treatment: the control side will be treated with metronidazole cream, the intervention side will be treated with a cold atmospheric plasma device
- Trial name
- NCT05592548
- Testing
- cold atmospheric plasma
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Skin Center Dermatology Group
Multiple Myeloma
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma
RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by…
- Trial name
- NCT01050790
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Virginia Commonwealth University
Multiple Myeloma
Elimination of Minimal Residual Disease After Transplant
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the…
- Trial name
- EMAT (NCT05690984)
- Testing
- Dexamethasone, Isatuximab, Lenalidomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Hip Necrosis, Hip Injuries
The Treatment of Initial Stage of Hip Osteonecrosis: the Core Decompression
This retrospective study evaluates 52 cases of avascular necrosis of femoral head (AVN) treated by core decompression, bone chips allograft, fibrin platelet rich-plasma (PRF) and concentrated autologous mesenchymal stromal cells…
- Trial name
- NEC15 (NCT04210440)
- Testing
- Core decompression procedure
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Dante Dallari, MD
Multiple Myeloma
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with approved regimens of either Lenalidomide Plus Dexamethasone [Len/Dex (Treatment A)] or Bortezomib Plus…
- Trial name
- DREAMM 6 (NCT03544281)
- Testing
- Belantamab mafodotin, Lenalidomide, Dexamethasone
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI
This study is designed to prospectively determine the sensitivity, specificity, and diagnostic accuracy of whole-body MRI (WBMRI) with Dual-Echo T2-weighted acquisition for Enhanced Conspicuity of Tumors (DETECT) for the…
- Trial name
- NCT04493411
- Testing
- WBMRI, Positron Emission Tomography/Computed Tomography (PET/CT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Texas Southwestern Medical Center
AL Amyloidosis (AL), t(11;14) Positive
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
The goal of this study is to evaluate the efficacy and safety of Sonrotoclax combined Regimen in patients with t(11;14) AL amyloidosis.
- Trial name
- NCT07335887
- Testing
- sonrotoclax, Daratumumab, Dexamethasone
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Peking University People's Hospital
Critical Illness, Multi Organ Failure
Parathyroid Hormone Kinetics During CRRT
The objective of this study is to assess the parathyroid hormone serum concentrations and kinetics in critically ill patients admitted to the intensive care unit due to multi-organ failure and undergoing citrate anticoagulation…
- Conditions
- Critical Illness, Multi Organ Failure, Renal Failure, Circulatory Failure
- Trial name
- NCT03873675
- Testing
- parathyroid hormone
- Where
- 3 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Uniwersytecki Szpital Kliniczny w Opolu
GERD
Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)
Background and Rationale: Gastroesophageal reflux disease is affecting 1 in 3 US adults with half experiencing daily symptoms. Per recent data, more than 50% continue to experience daily symptoms despite taking medical therapy…
- Trial name
- AREA (NCT06641375)
- Testing
- Anti reflux endoscopic theraphy, Endoscopy
- Where
- India
- Volunteers
- 18 people
- Sponsor
- Asian Institute of Gastroenterology, India
Multiple Myeloma
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor.
- Trial name
- NCT00005834
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 93 sites in United States
- Volunteers
- 19 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma, Refractory
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
The purpose of this study is to infuse BCMA CAR-NK cells（Umbilical \& Cord Blood (CB) Derived CAR-Engineered NK Cells） to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of…
- Trial name
- NCT05008536
- Testing
- Anti-BCMA CAR-NK Cells, Fludarabine, Cytoxan
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Xinqiao Hospital of Chongqing
Androgenetic Alopecia (AGA)
PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study
Research Purpose The objective of this study is to determine the safety and efficacy of combined PRP and BTX-A injection therapy for Androgenetic Alopecia (AGA).
- Trial name
- AGA (NCT07335367)
- Testing
- Injection of PRP combined with Botulinum Toxin Type A into the alopecic area(s), PRP-only injection into the alopecic area
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Leukemia, Lymphoma
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer
- Trial name
- NCT00005634
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hidradenitis Suppurativa (HS)
Neutralizing Interferon Type 1 in Hidradenitis Suppurativa
The purpose of the study is to evaluate the safety and type 1 Interferon (IFN) neutralization in patients with refractory severe Hidradenitis Suppurativa (Hurley stage III) after transfusion of plasma containing high titer…
- Trial name
- NIHS-I (NCT07067099)
- Testing
- Plasma with neutralizing autoantibodies to Type I Interferons
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439175
- Testing
- Taselisib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells in patients with relapsed or refractory multiple myeloma who received…
- Trial name
- NCT05998928
- Testing
- Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
- Trial name
- NCT00423644
- Testing
- Darinaparson
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Alaunos Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.